HSD111 Provider perspectives on the DREAMM-7 Trial Results and Belantamab Mafodotin (belamaf) in Combination with Bortezomib and Dexamethasone (B-Vd) as a Potential Treatment for Patients with Relapsed or Refractory Multiple Myeloma (R/R MM ...
Abstract
Authors
Sarah Lucht Yolaine Jeune-Smith Bhawna Gupta Nicholas Moffett Robert Bone Bruce Feinberg